Sleeping Beauty transposon system explained

The Sleeping Beauty transposon system is a synthetic DNA transposon designed to introduce precisely defined DNA sequences into the chromosomes of vertebrate animals for the purposes of introducing new traits and to discover new genes and their functions. It is a Tc1/mariner-type system, with the transposase resurrected from multiple inactive fish sequences.

Mechanism of action

The Sleeping Beauty transposon system is composed of a Sleeping Beauty (SB) transposase and a transposon that was designed in 1997 to insert specific sequences of DNA into genomes of vertebrate animals. DNA transposons translocate from one DNA site to another in a simple, cut-and-paste manner (Fig. 1). Transposition is a precise process in which a defined DNA segment is excised from one DNA molecule and moved to another site in the same or different DNA molecule or genome.[1]

As do all other Tc1/mariner-type transposases, SB transposase inserts a transposon into a TA dinucleotide base pair in a recipient DNA sequence.[2] The insertion site can be elsewhere in the same DNA molecule, or in another DNA molecule (or chromosome). In mammalian genomes, including humans, there are approximately 200 million TA sites. The TA insertion site is duplicated in the process of transposon integration. This duplication of the TA sequence is a hallmark of transposition and used to ascertain the mechanism in some experiments. However, a recent study indicated that SB also integrates into non-TA dinucleotides at a low frequency.[3] The transposase can be encoded either within the transposon (e.g., the putative transposon shown in Fig. 2) or the transposase can be supplied by another source, in which case the transposon becomes a non-autonomous element. Non-autonomous transposons (e.g., Fig. 1) are most useful as genetic tools because after insertion they cannot independently continue to excise and re-insert. All of the DNA transposons identified in the human genome and other mammalian genomes are non-autonomous because even though they contain transposase genes, the genes are non-functional and unable to generate a transposase that can mobilize the transposon.

Construction

This resurrected transposase gene was named "Sleeping Beauty (SB)" because it was brought back to activity from a long evolutionary sleep.[4] The SB transposon system is synthetic in that the SB transposase was re-constructed from extinct (fossil) transposase sequences belonging to the Tc1/mariner class of transposons[5] [6] found in the genomes of salmonid fish.[7] As in humans, where about 20,000 inactivated Tc1/mariner-type transposons comprise almost 3% of the human genome,[8] [9] the transposase genes found in fish have been inactive for more than 10 million years due to accumulated mutations. The reconstruction of SB transposase was based on the concept that there was a primordial Tc1-like transposon that was the ancestor to the sequences found in fish genomes. Although there were many sequences that looked like Tc-1 transposons in all the fish genomes studied, the transposon sequences were all inactive due to mutations. By assuming that the variations in sequences were due to independent mutations that accumulated in the different transposons, a putative ancestral transposon (Fig. 2) was postulated.[10]

The construction for the transposase began by fusing portions of two inactive transposon sequences from Atlantic salmon (Salmo salar) and one inactive transposon sequence from rainbow trout (Oncorhynchus mykiss) and then repairing small deficits in the functional domains of the transposase enzyme (Fig. 3). Each amino acid in the first completed transposase, called SB10, was determined by a “majority-rule consensus sequence” based on 12 partial genes found in eight fish species. The first steps (1->3 in Fig. 3) were to restore a complete protein by filling in gaps in the sequence and reversing termination codons that would keep the putative 360-amino acid polypeptide from being synthesized. The next step (4 in Fig. 3) was to reverse mutations in the nuclear localization signal (NLS) that is required to import the transposase enzyme from the cytoplasm where it is made to the nucleus where it acts. The amino-terminus of the transposase, which contains the DNA-binding motifs for recognition of the direct repeats (DRs), was restored in steps 5->8. The last two steps restored the catalytic domain, which features conserved aspartic acid (D) and glutamic acid (E) amino acids with specific spacing that are found in integrases and recombinases.[11] The result was SB10, which contains all of the motifs required for function.

SB10 transposase has been improved over the decade since its construction by increasing the consensus with a greater number of extinct Tc1 transposon sequences and testing various combinations of changes.[12] [13] [14] [15] [16] [17] Further work has shown that the DNA-binding domain consists of two paired sequences, which are homologous to sequence motifs found in certain transcription factors. The paired subdomains in SB transposase were designated PAI and RED. The PAI subdomain plays a dominant role in recognition of the DR sequences in the transposon. The RED subdomain overlaps with the nuclear localization signal, but its function remains unclear.[18] The most recent version of SB transposase, SB100X, has about 100 times the activity of SB10 as determined by transposition assays of antibiotic-resistance genes conducted in tissue cultured human HeLa cells.[16] The International Society for Molecular and Cell Biology and Biotechnology Protocols and Research (ISMCBBPR) named SB100X the molecule of the year for 2009 for recognition of the potential it has in future genome engineering.[19]

The transposon recognized by SB transposase was named T because it was isolated from the genome of another salmond fish, Tanichthys albonubes. The transposon consists of a genetic sequence of interest that is flanked by inverted repeats (IRs) that themselves contain short direct repeats (DR) (tandem arrowheads IR-DR in Figs. 1 and 2). T had the closest IR/DR sequence to the consensus sequence for the extinct Tc-1 like transposons in fish. The consensus transposon has IRs of 231 base pairs. The innermost DRs are 29 base pairs long whereas the outermost DRs are 31 base pairs long. The difference in length is critical for maximal transposition rates.[20] The original T transposon component of the SB transposon system has been improved with minor changes to conform to the consensus of many related extinct and active transposons.[20] [21]

Applications

Over the past decade, SB transposons have been developed as non-viral vectors for introduction of genes into genomes of vertebrate animals and for gene therapy. The genetic cargo can be an expression cassette—a transgene and associated elements that confer transcriptional regulation for expression at a desired level in specific tissue(s). An alternative use of SB transposons is to discover functions of genes, especially those that cause cancer,[22] [23] by delivering DNA sequences that maximally disrupt expression of genes close to the insertion site. This process is referred to as insertional mutagenesis or transposon mutagenesis. When a gene is inactivated by insertion of a transposon (or other mechanism), that gene is “knocked out”. Knockout mice and knockout rats have been made with the SB system.[24] [25] Figure 4 illustrates these two uses of SB transposons.

For either gene delivery or gene disruption, SB transposons combine the advantages of viruses and naked DNA. Viruses have been evolutionarily selected based on their abilities to infect and replicate in new host cells. Simultaneously, cells have evolved major molecular defense mechanisms to protect themselves against viral infections. For some applications of genome engineering such as some forms of gene therapy,[26] [27] [28] avoiding the use of viruses is also important for social and regulatory reasons. The use of non-viral vectors avoids many, but not all, of the defenses that cells employ against vectors.

Plasmids, the circular DNAs shown in Fig. 1, are generally used for non-viral gene delivery. However, there are two major problems with most methods for delivering DNA to cellular chromosomes using plasmids, the most common form of non-viral gene delivery. First, expression of transgenes from plasmids is brief due to lack of integration and due to cellular responses that turn off expression. Second, uptake of plasmid molecules into cells is difficult and inefficient. The Sleeping Beauty Transposon System was engineered to overcome the first problem. DNA transposons precisely insert defined DNA sequences (Fig. 1) almost randomly into host genomes thereby increasing the longevity of gene expression (even through multiple generations). Moreover, transposition avoids the formation of multiple, tandem integrations, which often results in switching off expression of the transgene. Currently, insertion of transgenes into chromosomes using plasmids is much less efficient than using viruses. However, by using powerful promoters to regulate expression of a transgene, delivery of transposons to a few cells can provide useful levels of secreted gene products for an entire animal.[29] [30]

Arguably the most exciting potential application of Sleeping Beauty transposons will be for human gene therapy. The widespread human application of gene therapy in first-world nations as well as countries with developing economies can be envisioned if the costs of the vector system are affordable. Because the SB system is composed solely of DNA, the costs of production and delivery are considerably reduced compared to viral vectors. The first clinical trials using SB transposons in genetically modified T cells will test the efficacy of this form of gene therapy in patients at risk of death from advanced malignancies.[31]

See also

Notes and References

  1. Plasterk RH . Molecular mechanisms of transposition and its control . Cell . 74 . 5 . 781–786 . September 1993 . 8397072 . 10.1016/0092-8674(93)90458-3 . 28784300 .
  2. Plasterk RH, Izsvák Z, Ivics Z . Resident aliens: the Tc1/mariner superfamily of transposable elements . Trends in Genetics . 15 . 8 . 326–332 . August 1999 . 10431195 . 10.1016/S0168-9525(99)01777-1 . free .
  3. Guo Y, Zhang Y, Hu K . Sleeping Beauty transposon integrates into non-TA dinucleotides . Mobile DNA . 9 . 8 . 2018 . 29445422 . 5801840 . 10.1186/s13100-018-0113-8 . free .
  4. Ivics Z, Hackett PB, Plasterk RH, Izsvák Z . Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells . Cell . 91 . 4 . 501–510 . November 1997 . 9390559 . 10.1016/S0092-8674(00)80436-5 . free .
  5. Doak TG, Doerder FP, Jahn CL, Herrick G . A proposed superfamily of transposase genes: transposon-like elements in ciliated protozoa and a common "D35E" motif . Proceedings of the National Academy of Sciences of the United States of America . 91 . 3 . 942–946 . February 1994 . 8302872 . 521429 . 10.1073/pnas.91.3.942 . free . 1994PNAS...91..942D .
  6. Radice AD, Bugaj B, Fitch DH, Emmons SW . Widespread occurrence of the Tc1 transposon family: Tc1-like transposons from teleost fish . Molecular & General Genetics . 244 . 6 . 606–612 . September 1994 . 7969029 . 10.1007/bf00282750 . 11381762 .
  7. Goodier JL, Davidson WS . Tc1 transposon-like sequences are widely distributed in salmonids . Journal of Molecular Biology . 241 . 1 . 26–34 . August 1994 . 8051704 . 10.1006/jmbi.1994.1470 .
  8. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA, Zinder N, Levine AJ, Roberts RJ, Simon M, Slayman C, Hunkapiller M, Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington K, Abu-Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R, Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z, Di Francesco V, Dunn P, Eilbeck K, Evangelista C, Gabrielian AE, Gan W, Ge W, Gong F, Gu Z, Guan P, Heiman TJ, Higgins ME, Ji RR, Ke Z, Ketchum KA, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov GV, Milshina N, Moore HM, Naik AK, Narayan VA, Neelam B, Nusskern D, Rusch DB, Salzberg S, Shao W, Shue B, Sun J, Wang Z, Wang A, Wang X, Wang J, Wei M, Wides R, Xiao C, Yan C, Yao A, Ye J, Zhan M, Zhang W, Zhang H, Zhao Q, Zheng L, Zhong F, Zhong W, Zhu S, Zhao S, Gilbert D, Baumhueter S, Spier G, Carter C, Cravchik A, Woodage T, Ali F, An H, Awe A, Baldwin D, Baden H, Barnstead M, Barrow I, Beeson K, Busam D, Carver A, Center A, Cheng ML, Curry L, Danaher S, Davenport L, Desilets R, Dietz S, Dodson K, Doup L, Ferriera S, Garg N, Gluecksmann A, Hart B, Haynes J, Haynes C, Heiner C, Hladun S, Hostin D, Houck J, Howland T, Ibegwam C, Johnson J, Kalush F, Kline L, Koduru S, Love A, Mann F, May D, McCawley S, McIntosh T, McMullen I, Moy M, Moy L, Murphy B, Nelson K, Pfannkoch C, Pratts E, Puri V, Qureshi H, Reardon M, Rodriguez R, Rogers YH, Romblad D, Ruhfel B, Scott R, Sitter C, Smallwood M, Stewart E, Strong R, Suh E, Thomas R, Tint NN, Tse S, Vech C, Wang G, Wetter J, Williams S, Williams M, Windsor S, Winn-Deen E, Wolfe K, Zaveri J, Zaveri K, Abril JF, Guigó R, Campbell MJ, Sjolander KV, Karlak B, Kejariwal A, Mi H, Lazareva B, Hatton T, Narechania A, Diemer K, Muruganujan A, Guo N, Sato S, Bafna V, Istrail S, Lippert R, Schwartz R, Walenz B, Yooseph S, Allen D, Basu A, Baxendale J, Blick L, Caminha M, Carnes-Stine J, Caulk P, Chiang YH, Coyne M, Dahlke C, Deslattes Mays A, Dombroski M, Donnelly M, Ely D, Esparham S, Fosler C, Gire H, Glanowski S, Glasser K, Glodek A, Gorokhov M, Graham K, Gropman B, Harris M, Heil J, Henderson S, Hoover J, Jennings D, Jordan C, Jordan J, Kasha J, Kagan L, Kraft C, Levitsky A, Lewis M, Liu X, Lopez J, Ma D, Majoros W, McDaniel J, Murphy S, Newman M, Nguyen T, Nguyen N, Nodell M, Pan S, Peck J, Peterson M, Rowe W, Sanders R, Scott J, Simpson M, Smith T, Sprague A, Stockwell T, Turner R, Venter E, Wang M, Wen M, Wu D, Wu M, Xia A, Zandieh A, Zhu X . The sequence of the human genome . Science . 291 . 5507 . 1304–1351 . February 2001 . 11181995 . 10.1126/science.1058040 . free . 2001Sci...291.1304V .
  9. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann Y, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Raymond C, Shimizu N, Kawasaki K, Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blöcker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglou S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kaspryzk A, Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowki J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S, Chen YJ, Szustakowki J . Initial sequencing and analysis of the human genome . Nature . 409 . 6822 . 860–921 . February 2001 . 11237011 . 10.1038/35057062 . free . 2001Natur.409..860L . 2027.42/62798 . free .
  10. Ivics Z, Izsvak Z, Minter A, Hackett PB . Identification of functional domains and evolution of Tc1-like transposable elements . Proceedings of the National Academy of Sciences of the United States of America . 93 . 10 . 5008–5013 . May 1996 . 8643520 . 39397 . 10.1073/pnas.93.10.5008 . free . 1996PNAS...93.5008I .
  11. Craig NL . Unity in transposition reactions . Science . 270 . 5234 . 253–254 . October 1995 . 7569973 . 10.1126/science.270.5234.253 . 29930180 . 1995Sci...270..253C .
  12. Geurts AM, Yang Y, Clark KJ, Liu G, Cui Z, Dupuy AJ, Bell JB, Largaespada DA, Hackett PB . Gene transfer into genomes of human cells by the sleeping beauty transposon system . Molecular Therapy . 8 . 1 . 108–117 . July 2003 . 12842434 . 10.1016/S1525-0016(03)00099-6 . free .
  13. Zayed H, Izsvák Z, Walisko O, Ivics Z . Development of hyperactive sleeping beauty transposon vectors by mutational analysis . Molecular Therapy . 9 . 2 . 292–304 . February 2004 . 14759813 . 10.1016/j.ymthe.2003.11.024 . free .
  14. Yant SR, Park J, Huang Y, Mikkelsen JG, Kay MA . Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells . Molecular and Cellular Biology . 24 . 20 . 9239–9247 . October 2004 . 15456893 . 517896 . 10.1128/MCB.24.20.9239-9247.2004 .
  15. Baus J, Liu L, Heggestad AD, Sanz S, Fletcher BS . Hyperactive transposase mutants of the Sleeping Beauty transposon . Molecular Therapy . 12 . 6 . 1148–1156 . December 2005 . 16150650 . 10.1016/j.ymthe.2005.06.484 . free .
  16. Mátés L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, Grzela DP, Schmitt A, Becker K, Matrai J, Ma L, Samara-Kuko E, Gysemans C, Pryputniewicz D, Miskey C, Fletcher B, VandenDriessche T, Ivics Z, Izsvák Z . Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates . Nature Genetics . 41 . 6 . 753–761 . June 2009 . 19412179 . 10.1038/ng.343 . 27373372 .
  17. Grabundzija I, Irgang M, Mátés L, Belay E, Matrai J, Gogol-Döring A, Kawakami K, Chen W, Ruiz P, Chuah MK, VandenDriessche T, Izsvák Z, Ivics Z . Comparative analysis of transposable element vector systems in human cells . Molecular Therapy . 18 . 6 . 1200–1209 . June 2010 . 20372108 . 2889740 . 10.1038/mt.2010.47 .
  18. Izsvák Z, Khare D, Behlke J, Heinemann U, Plasterk RH, Ivics Z . Involvement of a bifunctional, paired-like DNA-binding domain and a transpositional enhancer in Sleeping Beauty transposition . The Journal of Biological Chemistry . 277 . 37 . 34581–34588 . September 2002 . 12082109 . 10.1074/jbc.M204001200 . free .
  19. Web site: Vence T . "Sleeping Beauty" named Molecule of the Year . mdc-berlin.de . 10 May 2011.
  20. Cui Z, Geurts AM, Liu G, Kaufman CD, Hackett PB . Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon . Journal of Molecular Biology . 318 . 5 . 1221–1235 . May 2002 . 12083513 . 10.1016/S0022-2836(02)00237-1 .
  21. Izsvák Z, Ivics Z, Plasterk RH . Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates . Journal of Molecular Biology . 302 . 1 . 93–102 . September 2000 . 10964563 . 10.1006/jmbi.2000.4047 .
  22. Carlson CM, Largaespada DA . Insertional mutagenesis in mice: new perspectives and tools . Nature Reviews. Genetics . 6 . 7 . 568–580 . July 2005 . 15995698 . 10.1038/nrg1638 . 3194633 .
  23. Dupuy AJ . Transposon-based screens for cancer gene discovery in mouse models . Seminars in Cancer Biology . 20 . 4 . 261–268 . August 2010 . 20478384 . 2940989 . 10.1016/j.semcancer.2010.05.003 .
  24. Ivics Z, Izsvák Z . A whole lotta jumpin' goin' on: new transposon tools for vertebrate functional genomics . Trends in Genetics . 21 . 1 . 8–11 . January 2005 . 15680506 . 10.1016/j.tig.2004.11.008 .
  25. Jacob HJ, Lazar J, Dwinell MR, Moreno C, Geurts AM . Gene targeting in the rat: advances and opportunities . Trends in Genetics . 26 . 12 . 510–518 . December 2010 . 20869786 . 2991520 . 10.1016/j.tig.2010.08.006 .
  26. Izsvák Z, Ivics Z . Sleeping beauty transposition: biology and applications for molecular therapy . Molecular Therapy . 9 . 2 . 147–156 . February 2004 . 14759798 . 10.1016/j.ymthe.2003.11.009 . free .
  27. Book: Hackett PB, Ekker SC, Largaespada DA, McIvor RS . Sleeping Beauty Transposon-Mediated Gene Therapy for Prolonged Expression . Non-Viral Vectors for Gene Therapy, Second Edition: Part 2 . 54 . 189–232 . 2005 . 16096013 . 10.1016/S0065-2660(05)54009-4 . 978-0-12-017654-0 . Advances in Genetics .
  28. Aronovich EL, McIvor RS, Hackett PB . The Sleeping Beauty transposon system: a non-viral vector for gene therapy . Human Molecular Genetics . 20 . R1 . R14–R20 . April 2011 . 21459777 . 3095056 . 10.1093/hmg/ddr140 .
  29. Aronovich EL, Bell JB, Belur LR, Gunther R, Koniar B, Erickson DC, Schachern PA, Matise I, McIvor RS, Whitley CB, Hackett PB . Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses . The Journal of Gene Medicine . 9 . 5 . 403–415 . May 2007 . 17407189 . 1868578 . 10.1002/jgm.1028 .
  30. Aronovich EL, Bell JB, Khan SA, Belur LR, Gunther R, Koniar B, Schachern PA, Parker JB, Carlson CS, Whitley CB, McIvor RS, Gupta P, Hackett PB . Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system . Molecular Therapy . 17 . 7 . 1136–1144 . July 2009 . 19384290 . 2835207 . 10.1038/mt.2009.87 .
  31. Hackett PB, Largaespada DA, Cooper LJ . A transposon and transposase system for human application . Molecular Therapy . 18 . 4 . 674–683 . April 2010 . 20104209 . 2862530 . 10.1038/mt.2010.2 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sleeping Beauty transposon system".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.